Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ABT-450/ritonavir/ABT-267 (ombitasvir) and ABT-333 (dasabuvir) with ribavirin in treatment-experienced adults with hepatitis C genotype…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Compensated Cirrhosis
• Hepatitis C

Drugs mentioned

• ABT-267
• ABT-333 (ABT-333)
• ABT-450/ritonavir/ombitasvir (ombitasvir/ritonavir)
• Ribavirin (ribavirin)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Hepatitis C Infection, Compensated Cirrhosis | Phase 3 | Status: COMPLETED | Results posted: 2015-01-06